FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Pietrantonio F, Fucà G, Rossini D, Schmoll HJ, Bendell JC, Morano F, Antoniotti C, Corallo S, Borelli B, Raimondi A, Marmorino F, Niger M, Boccaccino A, Masi G, Lonardi S, Boni L, de Braud F, Di Bartolomeo M, Falcone A, Cremolini C.
Pietrantonio F, et al. Among authors: de braud f.
Oncologist. 2021 Apr;26(4):302-309. doi: 10.1002/onco.13642. Epub 2021 Jan 2.
Oncologist. 2021.
PMID: 33336844
Free PMC article.